Pesäkkeitä stimuloivan tekijän hoitomarkkinat: nykyinen analyysi ja ennuste (2024-2032)

$3999 - $6999

Painopiste tyypissä (makrofageja pesäkkeitä stimuloiva tekijä (M-CSF), useita pesäkkeitä stimuloiva tekijä tai interleukiini 3 (IL-3), granulosyytti-makrofagi-pesäkettä stimuloiva tekijä (GM-CSF), granulosyytti-pesäke- Stimuloiva tekijä (G-CSF)); Lääke (Pegfilgrastim, Tbo-filgrastim, Sargramostim, Filgrastim, muut); Sovellus (aplastinen anemia, luuydintransplantaatio, neutropenia, kemoterapiaan liittyvä neutropenia, säteilyyn liittyvä neutropenia, perifeerinen esisolun siirto); Loppukäyttäjä (sairaalat, erikoisklinikat, kotihoito, muut); Jakelukanava (sairaalaapteekit, vähittäiskaupan apteekit, verkkoapteekit); Alue/maa.

Sivuja:

151

Taulukko:

74

Kuvio:

105

Raportin tunnus:

UMHE212756

Maantiede:

Poista valinta
  Hanki näyte
Raportin kuvaus
Sisällysluettelo
Tutkimusmenetelmät

Raportin kuvaus

Colony-Stimulating Factor Therapy Market Forecast
Colony-Stimulating Factor Therapy Market Forecast

Colony-stimulating factor therapy Market Size & Forecast

- Colony-stimulating factor therapy Market was valued at USD ~8 Billion and is expected to grow at a strong CAGR of around 10.6% during the forecast period (2024-2032) owing rising prevalence of Cancer.

Colony-stimulating factor therapy Market Analysis

The colony stimulating factor (CSF) therapy market refers to the segment of the pharmaceutical industry focused on the development, production, and sale of medications known as colony stimulating factors. These medications are used to stimulate the production of white blood cells (specifically granulocytes, macrophages, and platelets) in patients whose immune systems are compromised due to conditions such as cancer, chemotherapy, bone marrow transplant, or certain infections. As the incidence of cancer continues to rise globally, the demand for colony stimulating factors, which are often used as supportive care in cancer treatment to manage chemotherapy-induced neutropenia, is also increasing. For instance, according to PAHO, in 2023,  Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer.  The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

Colony-Stimulating Factor Therapy Market Segment
Colony-Stimulating Factor Therapy Market Segment

Colony-stimulating factor therapy Market Trends

This section discusses the key market trends that are influencing the various segments of the Colony-stimulating factor therapy Market as identified by our team of research experts.

Hybrid Prosthetic Devices Transforming Industry

Advancements in Biotechnology and Drug Development: Biotechnology is playing a pivotal role in the development of novel CSF therapies with enhanced efficacy and safety profiles.

Researchers are leveraging cutting-edge techniques such as protein engineering, glycoengineering, and recombinant DNA technology to design next-generation CSF products.

By optimizing the structure and function of CSFs, biotechnology advancements aim to improve pharmacokinetics, reduce immunogenicity, and enhance therapeutic outcomes for cancer patients.

Personalized Medicine and Biomarker-driven Treatment: Personalized medicine approaches are gaining traction in the CSF therapy market, with a focus on tailoring treatment strategies to individual patient characteristics.

Biomarker-driven treatment algorithms help identify patients who are most likely to benefit from CSF therapy based on genetic, molecular, and clinical factors.

By matching patients with the most appropriate CSF therapy, personalized medicine approaches optimize treatment response rates, minimize adverse effects, and improve overall survival outcomes.

Koloniaa stimuloivan tekijän hoidon markkinatrendit
Koloniaa stimuloivan tekijän hoidon markkinatrendit

Pohjois-Amerikan odotetaan kasvavan merkittävällä CAGR:llä ennustejakson aikana

Biological Therapies and Immunomodulation: Biological therapies, including CSFs, are increasingly recognized for their immunomodulatory effects beyond their traditional role in stimulating white blood cell production.

Research is focusing on elucidating the mechanisms through which CSFs influence the immune system, including modulation of inflammatory responses, enhancement of antigen presentation, and regulation of immune cell function.

By harnessing the immunomodulatory properties of CSFs, researchers aim to develop novel therapeutic strategies for cancer and autoimmune diseases, as well as explore their potential in immunotherapy combinations.

Long-Acting Formulations and Drug Delivery Innovations:Pharmaceutical companies are investing in the development of long-acting formulations of CSFs to improve patient convenience and treatment adherence.

Novel drug delivery technologies, such as sustained-release formulations, polymer-based implants, and microneedle patches, offer prolonged drug release and reduced dosing frequency.

Long-acting formulations and drug delivery innovations enhance the pharmacokinetic profile of CSFs, providing sustained therapeutic effects while minimizing fluctuations in drug levels.

Colony-stimulating factor therapy Industry Overview

The colony-stimulating factor therapy market is competitive and fragmented, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd. , Pfizer Inc. , GlaxoSmithKline plc , Dr. Reddy’s Laboratories Ltd. , Amgen Inc. , Merck KGaA , Takeda Pharmaceutical Company Limited , Thermo Fisher Scientific Inc.

Colony-stimulating factor therapy Market News

  • In March 2023, Coherus BioSciences received U.S. FDA approval for its pegfilgrastim-cbqv (Udencya), a pegfilgrastim biosimilar for managing febrile neutropenia induced by chemotherapy.
  • In September 2022, Spectrum Pharmaceuticals, Inc. received U.S. FDA approval for its ROLVEDON (eflapegrastim-xnst) injection, which is intended to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid-malignancies-receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Colony-Stimulating Factor Therapy Market Report Coverage

Colony-Stimulating Factor Therapy Market Report Coverage
Colony-Stimulating Factor Therapy Market Report Coverage

Syyt tämän raportin ostamiseen:

  • Tutkimus sisältää markkinoiden mitoitus- ja ennusteanalyysin, jonka ovat validoineet todennettuja avainalan asiantuntijoita.
  • Raportti esittelee yhdellä silmäyksellä nopean katsauksen alan yleisestä suorituskyvystä.
  • Raportti kattaa syvällisen analyysin merkittävistä alan vertaisryhmistä keskittyen ensisijaisesti keskeisiin yritysten taloustietoihin, tuotesalkkuihin, laajentumisstrategioihin ja viimeaikaiseen kehitykseen.
  • Yksityiskohtainen tarkastelu alan kuljettajista, rajoituksista, tärkeimmistä trendeistä ja mahdollisuuksista.
  • Tutkimus kattaa kattavasti markkinat eri segmenteillä.
  • Alan aluetason syvällinen analyysi.

Mukautusvaihtoehdot:

The global colony-stimulating factor therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Usein kysytyt kysymykset (FAQ)

Q1: What is the current market size and growth potential of the colony-stimulating factor therapy market?

Ans: The colony-stimulating factor therapy market was valued at USD ~8 billion in 2023 and is expected to grow at a CAGR of 10.6% during the forecast period (2024-2032).

Q2: What are the driving factors for the growth of the colony-stimulating factor therapy market?

Ans: Rising prevalence of cancer and rising awareness among individuals are driving the colony-stimulating factor therapy market.

Q3: Which segment has the largest share of the colony-stimulating factor therapy market by type?

Ans: The granulocyte–colony-stimulating factor (G-CSF) segment has the largest share of the colony-stimulating factor therapy market by type.

Q4: What are the emerging technologies and trends in the colony-stimulating factor therapy market?

Ans: The advancement in biotechnology is one of the major trends in colony-stimulating factor therapy market.

Q5: Which region will dominate the colony-stimulating factor therapy market?

V: Pohjois-Amerikan odotetaan hallitsevan markkinoita ennustejaksolla.

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?

1.1.Markkinoiden määritelmät
1.2.Päätavoite
1.3.Sidosryhmät
1.4.rajoitus

 

2.1.Research Process of the Colony-Stimulating Factor Therapy Market
2.2.Research Methodology of the Colony-Stimulating Factor Therapy Market
2.4.Vastaajan profiili  

 

3MARKKINASYNOPSIS

 

4TIIVISTELMÄ

 

5IMPACT OF COVID-19 ON THE COLONY-STIMULATING FACTOR THERAPY MARKET 

 

6GLOBAL COLONY-STIMULATING FACTOR THERAPY MARKET REVENUE, 2022-2032F

 

7.1.Macrophage–Colony-Stimulating Factor (M-CSF)
7.2.Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
7.3.Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
7.4.Granulocyte–Colony-Stimulating Factor (G-CSF)

 

8.1.Pegfilgrastiimi
8.2.Tbo-filgrastim
8.3.Sargramostim
8.4.Filgrastim 
8.5.Muuta 

 

9.1.aplastinen anemia 
9.2.Luuydinsiirto
9.3.neutropenia 
9.4.Neutropenia Associated with Chemotherapy
9.5.Neutropenia Associated with Radiation
9.6.Peripheral Progenitor Cell Transplantation

 

10.1.Sairaalat 
10.2.Erikoisklinikat
10.3.Kotihoito
10.4.Muuta 

 

8.1.Sairaalaapteekit
8.2.Vähittäiskauppaapteekit
8.3.Online-apteekit

 

12.1NORTH AMERICA COLONY-STIMULATING FACTOR THERAPY MARKET  
 12.1.1.USA  
 12.1.2.Kanada  
 12.1.3.Muu Pohjois-Amerikka
12.2EUROPE COLONY-STIMULATING FACTOR THERAPY MARKET  
 12.2.1.Saksa  
 12.2.2.UK  
 12.2.3.Ranska  
 12.2.4.Italia  
 12.2.5.Espanja  
 12.2.6.Muu Eurooppa 
12.3ASIA PACIFIC COLONY-STIMULATING FACTOR THERAPY MARKET 
 12.3.1.Kiina  
 12.3.2.Japani  
 12.3.3.Intia  
 12.3.4.Muu Aasia-Tyynenmeren alue 
12.4REST OF THE WORLD COLONY-STIMULATING FACTOR THERAPY MARKET  

 

13.1.Markkinoiden kuljettajat
13.2.Markkinahaasteet
13.3.Vaikutusanalyysi

 

14COLONY-STIMULATING FACTOR THERAPY MARKET OPPORTUNITIES

 

15COLONY-STIMULATING FACTOR THERAPY MARKET TRENDS & INSIGHTS

 

16.1.Kysyntäpuolen analyysi
16.2.Tarjontapuolen analyysi

 

17ARVOKETJUANALYYSI

 

18HINTOJEN ANALYYSI 

 

19.1.kilpailutilanteessa
 19.1.1Porterin viiden voiman analyysi
20.1.Sanofi   
20.2.Novartis AG  
20.3.Teva lääketeollisuus Oy 
20.4.Pfizer Inc.  
20.5.GlaxoSmithKline plc  
20.6.Dr. Reddy's Laboratories Ltd. 
20.7.Amgen Inc.  
20.8.Merck KGaA  
20.9.Takedan lääkeyhtiö 
20.10.Thermo Fisher tieteellinen Inc.
21VASTUUVAPAUSLAUSEKE

Tutkimusmenetelmät

Research Methodology for the Colony-stimulating factor therapy Market Analysis (2024-2032)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global colony-stimulating factor therapy market were the three major steps undertaken to create and analyze the adoption of colony-stimulating factor therapy in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global colony-stimulating factor therapy market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Markkinoiden historiallisen koon analyysi

Vaihe 1: Toissijaisten lähteiden perusteellinen tutkimus:

Detail secondary study was conducted to obtain the historical market size of the colony-stimulating factor therapy market through company internal sources such as vuosikertomukset ja tilinpäätökset, tulosesittelyt, lehdistötiedotteet jne., ja ulkoisista lähteistä mukaan lukien lehdet, uutiset ja artikkelit, hallituksen julkaisut, kilpailijoiden julkaisut, sektoriraportit, kolmannen osapuolen tietokannat ja muut uskottavat julkaisut.

Vaihe 2: Markkinoiden segmentointi:

After obtaining the historical market size of the colony-stimulating factor therapy market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as type, drug, application end-user and distribution channel. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Vaihe 3: tekijäanalyysi:

Hankittuamme eri segmenttien ja alasegmenttien historiallisen markkinakoon, teimme yksityiskohtaisen tekijäanalyysi to estimate the current market size of the colony-stimulating factor therapy market. Further, we conducted factor analysis using dependent and independent variables such as type, drug, application end-user and distribution channel of the colony-stimulating factor therapy market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the colony-stimulating factor therapy market sector across the globe.

Nykyinen markkinakokoarvio ja ennuste

Nykyinen markkinakoko: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global colony-stimulating factor therapy market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Arvio ja ennusteet: Markkinoiden arvioinnissa ja ennusteissa painotettiin eri tekijöitä, kuten tekijöitä ja trendejä, rajoituksia ja sidosryhmien käytettävissä olevia mahdollisuuksia. Näiden tekijöiden analysoinnin jälkeen sovellettiin asiaankuuluvia ennustetekniikoita eli ylhäältä alas/alhaalta ylös -lähestymistapaa, jotta saatiin aikaan markkinaennuste vuodelle 2030 eri segmenteillä ja alasegmenteillä tärkeimmillä markkinoilla maailmanlaajuisesti. Markkinoiden koon arvioimiseksi käytetty tutkimusmetodologia sisältää:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of the colony-stimulating factor therapy market across the major markets domestically
  • Kaikki prosenttiosuudet, splitit ja markkinasegmenttien ja alasegmenttien erittelyt
  • Key players in the global colony-stimulating factor therapy market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Markkinoiden koon ja osuuden vahvistaminen

Perustutkimus: Tärkeimmillä alueilla suoritettiin perusteellisia haastatteluja tärkeimpien mielipidejohtajien (KOL) kanssa, mukaan lukien ylimmän tason johtajat (CXO/VP:t, myyntipäällikkö, markkinointipäällikkö, operatiivinen johtaja, aluejohtaja, maajohtaja jne.). Ensisijaiset tutkimustulokset koottiin sitten yhteen ja suoritettiin tilastollinen analyysi esitetyn hypoteesin todistamiseksi. Primääritutkimuksen panokset yhdistettiin toissijaisiin havaintoihin, jolloin tieto muutettiin käyttökelpoisiksi oivalluksiksi.

Ensisijaisten osallistujien jakautuminen eri alueilla

Colony-Stimulating Factor Therapy Market Graph
Colony-Stimulating Factor Therapy Market Graph

Markkinasuunnittelu

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global colony-stimulating factor therapy market. data was split into several segments & sub-segments post studying various parameters and trends in the areas of the as type, drug, application end-user and distribution channel in the global colony-stimulating factor therapy market.

The main objective of the Global Colony-stimulating factor therapy Market Study

The current & future market trends of the global colony-stimulating factor therapy market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the colony-stimulating factor therapy market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of the as type, drug, application end-user and distribution channel
  • Define and analysis of the regulatory framework for the colony-stimulating factor therapy industry
  • Analysoi arvoketjua, joka liittyy erilaisten välittäjien läsnäoloon, sekä analysoi alan asiakkaiden ja kilpailijoiden käyttäytymistä
  • Analyze the current and forecast market size of the colony-stimulating factor therapy market for the major region
  • Suurimpia raportissa tutkittuja alueita ovat Aasia ja Tyynenmeren alue, Eurooppa, Pohjois-Amerikka ja muu maailma
  • Company profiles of the colony-stimulating factor therapy market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Alan aluetason syvällinen analyysi

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?